New study tracks Cancer's genetic secrets during therapy
NCT ID NCT03712566
First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This research study looks at how certain cancers (head and neck, esophagus, and anal canal) change at the genetic and immune level when patients receive chemotherapy or immunotherapy. About 39 people with advanced cancer will provide blood samples and tumor tissue over time. The goal is to better understand how these cancers respond to treatment, not to test a new drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
39 people
The number who actually took part.
- Started
-
Nov 2018
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with a diagnosis of squamous cell cancer of the head \& neck, esophagus, or anal canal who have radiologically confirmed recurrent or metastatic disease.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients with a histological or cytological diagnosis of Squamous Cell Cancer of the head and neck, esophagus or anal canal who have radiologically confirmed recurrent or metastatic disease. 2. Patients must be of adequate fitness, ECOG 0-1 for systemic therapy, with either standard chemotherapy, immunotherapy or within the context of a clinical trial. 3. Patients must be commencing on a new treatment at time of consent, this can be first line platinum based chemotherapy, or immunotherapy, any line. 4. Patients must be ≥ 18 years old. 5. Patients must have provided voluntary written informed consent. Exclusion Criteria: None
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anal canal squamous cell carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a personal navigator help young cancer patients through treatment?
- Can a smartwatch predict which cancer patients return to hospital?
- Two-Drug combo aims to stall advanced breast cancer
- Blood thinner flush could boost tumor biopsy success
- Could a frailty score predict which older cancer patients survive intensive care?